Evidence map›Paper›PMID 31374106›Full record

ArticlePloS one2019

Intervention changes acoustic peak frequency and mesolimbic neurochemistry in the Pink1-/- rat model of Parkinson disease.

Sharon A Stevenson, Michelle R Ciucci, Cynthia A Kelm-Nelson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Predictors of prodromal Parkinson's disease in young adultFrontiers in behavioral neuroscience · 2022
    Article
  6. Article
  7. Review
  8. Pink1Brain communications · 2021
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sharon A StevensonDepartment of Surgery, Division of Otolaryngology, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Michelle R CiucciDepartment of Surgery, Division of Otolaryngology, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Cynthia A Kelm-NelsonDepartment of Surgery, Division of Otolaryngology, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0001-6670-2177
University of Wisconsin–Madison · US

Funding

Influence of neuromuscular pathology on parkinsonian communication deficitsR01DC014358 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI CIUCCI, MICHELLE RENEE, CONNOR, NADINE P · 2015 to 2019
$2.7M
Communication dysfunction in Parkinson disease: Integrated genetic and protein expression analysis of neural pathways to identify treatment targetsR21DC016135 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI KELM-NELSON, CYNTHIA A · 2018 to 2020
$459k
Pathology and treatment of vocal deficits in Parkinson diseaseF32DC014399 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI KELM-NELSON, CYNTHIA A · 2014 to 2016
$163k
NIDCD NIH HHS F32 DC014399NIDCD NIH HHS R01 DC014358NIDCD NIH HHS R21 DC016135
6 · The paper itself

Abstract

The neural mechanisms underlying behavioral therapy for vocal acoustic deficits in patients with Parkinson disease is unknown. A primary hypothesis is that voice therapy may modulate mesolimbic brainstem regions, including the ventral tegmental area (VTA). The VTA is implicated in ultrasonic call peak frequency, involved in rewarding behaviors, and impacted by Parkinsonism. We tested the hypothesis that chronic (daily) behavioral vocal exercise of male Pink1-/- rats would alter ultrasonic vocalization acoustics and mesolimbic neurochemistry (catecholamines, GABA, mu-opioid receptor) compared to three different controls: sham-exercised Pink1-/-, unexercised Pink1-/-, and unexercised wildtype (WT) rats. A sub-hypothesis is that sham-exercise rats may exhibit changes to VTA neurochemistry as a result of a type or rewarding intervention. Results demonstrate that average bandwidth (frequency range) of ultrasonic vocalizations did not differ between WT, Pink1-/- no exercise vs. sham and vocal-exercise rats. However, average peak frequency is significantly reduced in vocal-exercised Pink1-/- rats compared to Pink1-/- no exercise, and WT groups. Unexpectedly, there were no significant acoustic differences between the vocal- and sham-exercised groups. There were no differences in catecholamine protein concentrations or tyrosine hydroxylase mRNA expression in the VTA between any of the groups. However, there was significant upregulation of all GABA-related genes in both vocal- and sham-exercised Pink1-/- rats (Gad1, Gad2, Gls, Glul); this finding was confirmed with follow up quantitative Western blotting for GAD. Additionally, there were differential results for mu-opioid receptor quantification in the VTA: vocal-exercised Pink1-/- rats showed increased mRNA expression for mu-opioid receptors whereas Western blotting indicated decreased protein levels in all Pink1-/- rats compared to WT controls suggesting the possible onset of pathology in this model. These data demonstrate modulatory effects of a rewarding behavioral paradigm on ultrasonic vocalization peak frequency. The results suggest that neuromodulators such as GABA and opioid activity, as well as the rewarding aspects of therapy may play a key role in shaping vocal treatments.

Indexed as

AnimalsAnimals, Genetically ModifiedCatecholaminesDisease Models, Animalgamma-Aminobutyric AcidMaleParkinson DiseaseProtein KinasesPTEN-Induced Putative KinaseRatsReceptors, Opioid, muTyrosine 3-MonooxygenaseVentral Tegmental AreaVocalization, AnimalCatecholaminesgamma-Aminobutyric AcidProtein KinasesPTEN-Induced Putative KinaseReceptors, Opioid, muTyrosine 3-Monooxygenase

Identifiers

PMID31374106
PMCPMC6677310
OpenAlexW2964354144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.